The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis
The germline JAK2 46/1 haplotype has been associated with the development of JAK2V617F-positive as well as JAK2V617F-negative myeloproliferative neoplasms (MPNs). In this study we examined the role of the 46/1 haplotype in the etiology and clinical presentation of patients with splanchnic vein thrombosis (SVT), in which MPNs are the most prominent underlying etiological factor. The singlenucleotide polymorphism rs12343867, which tags 46/1, was genotyped in 199 SVT patients. The 46/1 haplotype was overrepresented in JAK2V617F-positive SVT patients compared with controls (P<.01). Prevalence of the 46/1 haplotype in JAK2V617F-negative SVT patients did not differ from prevalence in the controls. However, JAK2V617F-negative SVT patients with a proven MPN also exhibited an increased frequency of the 46/1 haplotype (P =.06). Interestingly, 46/1 was associated with increased erythropoiesis in JAK2V617F-negative SVT patients. We conclude that the 46/1 haplotype is associated with the development of JAK2V617F-positive SVT. In addition, our findings in JAK2V617F-negative SVT patients indicate an important role for the 46/1 haplotype in the etiology and diagnosis of SVT-related MPNs, independent of JAK2V617F, that requires further exploration.
|Persistent URL||dx.doi.org/10.1182/blood-2010-11-319087, hdl.handle.net/1765/26484|
|Note||Free full text at PubMed|
Smalberg, J.H., Murad, S.D., Koehler, E.M., Plessier, A., Seijo, S., Trebicka, J., … Leebeek, F.W.G.. (2011). The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood, 117(15), 3968–3973. doi:10.1182/blood-2010-11-319087